Abstract: Background Infection after prostate biopsy (IAPB) occurs in 2-6% of cases. Due to fluoroquinolone resistance at our facility, preprocedural prophylaxis for prostate biopsy was switched from Ciprofloxacin to Fosfomycin in 2017. However, the rates of IAPB at our facility increased from 0.93% to 4.27% between 2021 and 2022 (Figure 1). Herein we describe the impact of a series of interventions aimed at reducing the IAPB rate. Table One Methods A multidisciplinary workgroup including infection control, antimicrobial stewardship, nursing, and urology was convened in February 2022. An outbreak investigation ensued utilizing active surveillance, direct procedural observation, and chart review for epidemiologic commonalities and appropriateness antibiotics (Table 1). Based on these findings, several interventions were implemented (Table 1). IAPB rates were modelled over time using a generalized additive spline model with 2 knots. Data analysis took place between Oct 2018 to Sept 2023 using SAS Statistical Software (version 9.4. Cary, NC, USA). Figure One Results A total of 2,295 prostate biopsies and 37 infections were identified from Oct 2018 to Sept 2023. Numerous bacterial pathogens were implicated, and no point source of infection was identified. Multilocus sequence-typing of three Klebsiella pneumoniae isolates did not suggest a single-organism outbreak. Pseudomonas was implicated in 4 infections. Fosfomycin minimum inhibitory concentrations were elevated in 6/9 isolates available for testing (range 32 to >1024 ug/mL). Three periods with different infection rates were identified (Figure 2). Mean infection rates were 1% (0.6%-1.7%) for the first period (Oct 2018 to Aug 2021), 4.4% (2.8%-6.7%) for the second (Sept 2021 to Oct 2022), and 0.7% (0.2%-2.0%) for the third (Nov 2022 to Sept 2023). Periods one and three had statistically significant lower infection rates than period two (p=0.0002 and p=0.004, respectively). Conclusion A multidisciplinary workgroup applying a series of interventions was ...
No Comments.